News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
70,479 Results
Type
Article (6247)
Company Profile (13)
Press Release (64219)
Multimedia
Podcasts (69)
Webinars (8)
Section
Business (25578)
Career Advice (161)
Deals (4342)
Drug Delivery (54)
Drug Development (6655)
Employer Resources (18)
FDA (1244)
Job Trends (1723)
News (36529)
Policy (2286)
Tag
Academia (284)
Accelerated approval (6)
Adcomms (5)
Allergies (8)
Alliances (6148)
ALS (19)
Alzheimer's disease (317)
Antibody-drug conjugate (ADC) (35)
Approvals (1227)
Artificial intelligence (112)
Autoimmune disease (27)
Automation (4)
Bankruptcy (34)
Best Places to Work (1264)
BIOSECURE Act (4)
Biosimilars (27)
Biotechnology (14)
Bladder cancer (6)
Brain cancer (3)
Breast cancer (44)
Cancer (391)
Cardiovascular disease (78)
Career advice (135)
Career pathing (8)
CAR-T (29)
CDC (3)
Cell therapy (87)
Clinical research (5250)
Collaboration (271)
Compensation (13)
Complete response letters (8)
COVID-19 (337)
CRISPR (18)
C-suite (192)
Cystic fibrosis (16)
Data (404)
Denatured (2)
Depression (15)
Diabetes (135)
Diagnostics (660)
Digital health (10)
Diversity (2)
Diversity, equity & inclusion (5)
Drug discovery (58)
Drug pricing (91)
Drug shortages (25)
Duchenne muscular dystrophy (16)
Earnings (5665)
Editorial (27)
Employer branding (1)
Employer resources (16)
Events (6638)
Executive appointments (223)
FDA (1502)
Friedreich's ataxia (1)
Frontotemporal dementia (4)
Funding (693)
Gene editing (40)
Generative AI (11)
Gene therapy (98)
GLP-1 (558)
Government (429)
Guidances (33)
Healthcare (1550)
HIV (6)
Huntington's disease (3)
IgA nephropathy (8)
Immunology and inflammation (54)
Immuno-oncology (11)
Indications (8)
Infectious disease (355)
Inflammatory bowel disease (32)
Inflation Reduction Act (7)
Influenza (4)
Intellectual property (22)
Interviews (24)
IPO (1985)
IRA (19)
Job creations (466)
Job search strategy (121)
JPM (30)
Labor market (24)
Layoffs (82)
Leadership (8)
Legal (525)
Liver cancer (6)
Longevity (3)
Lung cancer (51)
Lymphoma (32)
Machine learning (12)
Management (5)
Manufacturing (170)
MASH (29)
Medical device (1382)
Medtech (1392)
Mergers & acquisitions (2502)
Metabolic disorders (530)
Multiple sclerosis (9)
NASH (7)
Neurodegenerative disease (77)
Neuropsychiatric disorders (17)
Neuroscience (444)
Neurotech (1)
NextGen: Class of 2026 (1073)
Non-profit (371)
Now hiring (36)
Obesity (369)
Opinion (94)
Ovarian cancer (13)
Pain (20)
Pancreatic cancer (8)
Parkinson's disease (24)
Partnered (8)
Patents (25)
Patient recruitment (55)
Peanut (5)
People (10755)
Pharmaceutical (5)
Pharmacy benefit managers (2)
Phase 1 (1630)
Phase 2 (2192)
Phase 3 (1939)
Pipeline (426)
Policy (94)
Postmarket research (241)
Preclinical (739)
Press Release (6)
Prostate cancer (19)
Psychedelics (14)
Radiopharmaceuticals (59)
Rare diseases (93)
Real estate (672)
Recruiting (7)
Regulatory (1801)
Reports (7)
Research institute (217)
Resumes & cover letters (22)
Rett syndrome (3)
RNA editing (4)
RSV (2)
Schizophrenia (14)
Series A (188)
Series B (140)
Sickle cell disease (4)
Special edition (12)
Spinal muscular atrophy (6)
Sponsored (3)
Startups (2237)
Supply chain (23)
Tariffs (59)
The Weekly (67)
Vaccines (67)
Venture capital (81)
Weight loss (327)
Women's health (7)
Date
Last 7 days (65)
Last 30 days (254)
Last 365 days (3237)
2026 (337)
2025 (3330)
2024 (3771)
2023 (3813)
2022 (6594)
2021 (5996)
2020 (5679)
2019 (5196)
2018 (4048)
2017 (3583)
2016 (3004)
2015 (3426)
2014 (2467)
2013 (2092)
2012 (2191)
2011 (2445)
2010 (2470)
Location
Africa (98)
Alabama (12)
Alaska (2)
Arizona (18)
Arkansas (5)
Asia (5172)
Australia (610)
California (1114)
Canada (765)
China (195)
Colorado (41)
Connecticut (37)
Delaware (15)
Europe (10046)
Florida (77)
Georgia (32)
Hawaii (2)
Idaho (5)
Illinois (65)
India (18)
Indiana (225)
Iowa (3)
Japan (51)
Kansas (7)
Kentucky (5)
Louisiana (6)
Maine (6)
Maryland (82)
Massachusetts (647)
Michigan (20)
Minnesota (30)
Mississippi (1)
Missouri (17)
Montana (1)
Nebraska (2)
Nevada (15)
New Hampshire (8)
New Jersey (185)
New Mexico (4)
New York (223)
North Carolina (147)
Northern California (556)
Ohio (55)
Oklahoma (4)
Oregon (5)
Pennsylvania (140)
Puerto Rico (5)
Rhode Island (7)
South America (127)
South Carolina (8)
Southern California (391)
Tennessee (12)
Texas (96)
United States (3300)
Utah (35)
Virginia (24)
Washington D.C. (14)
Washington State (74)
West Virginia (1)
Wisconsin (14)
70,479 Results for "lilly ventures".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Immunology and inflammation
Lilly Establishes up to $1.9B Repertoire Deal in Second Immune Play of 2026
The Repertoire partnership is Lilly’s second immunology play of the year, after the acquistion of Ventyx in early January for a pipeline of NLRP3 assets.
January 29, 2026
·
2 min read
·
Tristan Manalac
Obesity
Lilly’s Obesity Pill Maintains Weight Loss as Estimated Approval Timelines Inch Closer
Participants in a Phase III trial who switched to Eli Lilly’s orforglipron after 72 weeks of treatment with Wegovy or Zepbound largely maintained their weight loss for up to a year.
December 18, 2025
·
2 min read
·
Tristan Manalac
Manufacturing
Eli Lilly Commits $3.5B To Build Injectable Obesity Drug Plant in PA
The facility, which is part of Lilly’s $50 billion reshoring drive, will make obesity drugs such as tirzepatide and retatrutide when it starts operations in 2031.
February 2, 2026
·
2 min read
·
Nick Paul Taylor
Weight Loss
Lilly’s Path to $94B in Revenue Rests on Oral Obesity Market and Other 2026 Milestones
The fierce rivalry between Novo Nordisk and Eli Lilly is alive and well, as the two companies are expected to face off with their new obesity pills this year.
January 5, 2026
·
3 min read
·
Annalee Armstrong
Podcast
JPM26 Recap, Novo’s Oral Wegovy Soars as Lilly’s Orforglipron Is Delayed, IPOs Return
The obesity market and Most Favored Nation drug pricing were among the topics de jour at the J.P. Morgan Healthcare Conference last week, while smaller biotechs sought to assure investors that their regulatory ducks are in a row; Novo Nordisk’s oral obesity pill got off to a hot start while the FDA delayed a decision on Eli Lilly’s investigational offering; and SpyGlass Pharma and AgomAb Therapeutics join the 2026 IPO club.
January 21, 2026
·
1 min read
·
Heather McKenzie
Editorial
Novo Will Never Beat Lilly. Why Does It Have To?
Novo Nordisk and Eli Lilly have been battling head-to-head in an exploding obesity market. They should never have been compared apples to apples.
February 5, 2026
·
3 min read
·
Annalee Armstrong
Weight loss
Lilly Redefines the Pharma Mega-Blockbuster
Previous mega blockbusters took years to reach their peak sales. Lilly’s tirzepatide franchise is on course to exceed them just a few years in.
November 25, 2025
·
2 min read
·
Annalee Armstrong
Gene editing
Lilly Leans Into Hearing Loss in $1.12B+ Gene Editing Pact With Seamless
The deal will help bolster Eli Lilly’s growing hearing loss portfolio, which is anchored by the gene therapy AK-OTOF.
January 28, 2026
·
2 min read
·
Tristan Manalac
pipeline
Lilly Axes 3 Therapies Amid Pipeline-in-a-Product Push for GLP-1
One of the assets shelved by Eli Lilly is a gene therapy for dementia, which it obtained in its $1.04-billion acquisition of Prevail Therapeutics in late 2020.
February 5, 2026
·
2 min read
·
Tristan Manalac
Immunology and inflammation
Lilly Eyes Pipeline in a Product as GLP-1s Move Into I&I
In addition to claiming revenue of $19.3 billion for the fourth quarter, Eli Lilly executives offered a glimpse into their strategy to expand their GLP-1 franchise into the immunology and inflammation space, with trials currently underway in asthma, psoriatic arthritis, Crohn’s disease and ulcerative colitis.
February 4, 2026
·
2 min read
·
Heather McKenzie
1 of 7,048
Next